StockMacro
Menu

Protalix BioTherapeutics

$2.90 +36% in 6 monthsMarket cap $244.5M

PLX on XASE, Health Care, Protalix BioTherapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Net income jumped 281% to $20.6M as revenue rose 37% over the last 12 months.

  • GoodLatest quarter revenue rose 23% to $21.9M
  • GoodFree cash flow of $15.1M over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
226
Website
protalix.com
Listed
NYSE American, US
Last results
10 Nov 2026
Next results
expected around 17 Mar 2027 (an estimate: a year ago it reported on 18 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $21.9M, net income $4.0M.
Quarter to 31 Dec 2021: revenue $8.5M, net income -$6.7MQuarter to 31 Dec 2021: revenue $8.5M, net income -$6.7MQuarter to 31 Mar 2022: revenue $16.1M, net income -$2.3MQuarter to 31 Mar 2022: revenue $16.1M, net income -$2.3MQuarter to 30 Jun 2022: revenue $8.8M, net income -$5.3MQuarter to 30 Jun 2022: revenue $8.8M, net income -$5.3MQuarter to 30 Sep 2022: revenue $14.2M, net income -$3.6MQuarter to 30 Sep 2022: revenue $14.2M, net income -$3.6MQuarter to 31 Dec 2022: revenue $8.6M, net income -$3.7MQuarter to 31 Dec 2022: revenue $8.6M, net income -$3.7MQuarter to 31 Mar 2023: revenue $9.6M, net income -$3.1MQuarter to 31 Mar 2023: revenue $9.6M, net income -$3.1MQuarter to 30 Jun 2023: revenue $35.1M, net income $19.3MQuarter to 30 Jun 2023: revenue $35.1M, net income $19.3MQuarter to 30 Sep 2023: revenue $10.3M, net income -$1.9MQuarter to 30 Sep 2023: revenue $10.3M, net income -$1.9MQuarter to 31 Dec 2023: revenue $10.5M, net income -$6.0MQuarter to 31 Dec 2023: revenue $10.5M, net income -$6.0MQuarter to 31 Mar 2024: revenue $3.7M, net income -$4.6MQuarter to 31 Mar 2024: revenue $3.7M, net income -$4.6MQuarter to 30 Jun 2024: revenue $13.5M, net income -$2.2MQuarter to 30 Jun 2024: revenue $13.5M, net income -$2.2MQuarter to 30 Sep 2024: revenue $18.0M, net income $3.2MQuarter to 30 Sep 2024: revenue $18.0M, net income $3.2MQuarter to 31 Dec 2024: revenue $18.2M, net income $6.5MQuarter to 31 Dec 2024: revenue $18.2M, net income $6.5MQuarter to 31 Mar 2025: revenue $10.1M, net income -$3.6MQuarter to 31 Mar 2025: revenue $10.1M, net income -$3.6MQuarter to 30 Jun 2025: revenue $15.7M, net income $164KQuarter to 30 Jun 2025: revenue $15.7M, net income $164KQuarter to 30 Sep 2025: revenue $17.9M, net income $2.4MQuarter to 30 Sep 2025: revenue $17.9M, net income $2.4MQuarter to 31 Dec 2025: revenue $9.1M, net income -$5.5MQuarter to 31 Dec 2025: revenue $9.1M, net income -$5.5MQuarter to 31 Mar 2026: revenue $33.8M, net income $18.3MQuarter to 31 Mar 2026: revenue $33.8M, net income $18.3MQuarter to 30 Jun 2026: revenue $19.9M, net income $3.8MQuarter to 30 Jun 2026: revenue $19.9M, net income $3.8MQuarter to 30 Sep 2026: revenue $21.9M, net income $4.0MQuarter to 30 Sep 2026: revenue $21.9M, net income $4.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $35.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$21.9M$4.0M
30 Jun 2026$19.9M$3.8M
31 Mar 2026$33.8M$18.3M
31 Dec 2025$9.1M-$5.5M
30 Sep 2025$17.9M$2.4M
30 Jun 2025$15.7M$164K
31 Mar 2025$10.1M-$3.6M
31 Dec 2024$18.2M$6.5M
30 Sep 2024$18.0M$3.2M
30 Jun 2024$13.5M-$2.2M
31 Mar 2024$3.7M-$4.6M
31 Dec 2023$10.5M-$6.0M
30 Sep 2023$10.3M-$1.9M
30 Jun 2023$35.1M$19.3M
31 Mar 2023$9.6M-$3.1M
31 Dec 2022$8.6M-$3.7M
30 Sep 2022$14.2M-$3.6M
30 Jun 2022$8.8M-$5.3M
31 Mar 2022$16.1M-$2.3M
31 Dec 2021$8.5M-$6.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $84.7M $61.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +37% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $20.6M $5.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.25 $0.07
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 71.2% 57.5% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 29.8% 10.3% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 24.3% 8.7% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 30.8% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $15.1M -$11.7M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $22.0M $13.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$22.0M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.96
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 11.9 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.9 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.6 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.0 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Protalix BioTherapeuticsPLX (this company) $244.5M11.92.9+37%24.3%
Lexeo TherapeuticsLXEO $245.1Mloss–––
Editas MedicineEDIT $253.1Mloss5.1+7.4%-145%
SAB BiotherapeuticsSABS $253.1Mloss–––
Eikon TherapeuticsEIKN $256.8M––––
OcugenOCGN $260.6Mloss54.5-11%–

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.0%

106 13F filers vs 101

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

19%

15.8M shares held by 13F filers (30 Sep 2026) of 84.3M outstanding (1 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.1%

3.5M shares sold short (30 Oct 2026) of 84.3M outstanding (1 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.2

3.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-0.8%

3.5M shares sold short in the report before, 3.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

40%

40% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 45%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+23%

$21.9M vs $17.9M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

2

2 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

2 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $2.90 on 20 Nov 2026, +67% over 12 months (12-month range $1.67 to $3.15)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $101K in the last 12 months (the 12 months before: $206K).
Revenue per quarter. Revenue $21.9M in the latest quarter, +23% on a year earlier.
Capital spending per quarter. Capital spending $737K in the latest quarter, +48% on a year earlier.
Institutional holders (13F filers). 106 13F filers reported holding it in the latest 13F quarter, +39% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
14 May 2026Sharp changeQuarterly revenue change: quarterly revenue change, 33.8M vs usual 14.6M (2026-03-31); 3.3x the same period a year earlier
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 27 vs usual 8.50 (2025-06-30); 1.1x the same period a year earlier
21 Jul 20258-K and other filingsDirector or officer change
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 21 vs usual 8.50 (2025-03-31); 3.0x the same period a year earlier
23 Apr 20258-K and other filingsDirector or officer change
23 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 7.50 (2024-06-30); 0.8x the same period a year earlier
12 Sep 20238-K and other filingsDirector or officer change
12 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 33 vs usual 4.50 (2023-06-30); 8.2x the same period a year earlier
8 Aug 2023Sharp changeQuarterly revenue change: quarterly revenue change, 35.1M vs usual 9.2M (2023-06-30); 4.0x the same period a year earlier
1 Aug 2023Sharp changeShort interest spike: short interest spike, 6.3M vs usual 2.1M (2023-07-14); 2.9x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 7.3M vs usual 2.1M (2023-06-30); 3.1x the same period a year earlier
4 Jul 2023Sharp changeShort interest spike: short interest spike, 7.0M vs usual 2.1M (2023-06-15); 2.7x the same period a year earlier
13 Jun 2023Sharp changeShort interest spike: short interest spike, 7.3M vs usual 2.1M (2023-05-31); 2.7x the same period a year earlier
30 May 2023Sharp changeShort interest spike: short interest spike, 8.1M vs usual 2.1M (2023-05-15); 2.1x the same period a year earlier
16 May 2023Sharp changeShort interest spike: short interest spike, 7.4M vs usual 2.1M (2023-04-28); 1.6x the same period a year earlier
2 May 2023Sharp changeShort interest spike: short interest spike, 6.4M vs usual 2.1M (2023-04-14); 1.1x the same period a year earlier
18 Apr 2023Sharp changeShort interest spike: short interest spike, 5.4M vs usual 2.1M (2023-03-31); 1.3x the same period a year earlier
30 Jun 20228-K and other filingsDirector or officer change
30 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Nov 2021Sharp changeShort interest spike: short interest spike, 6.6M vs usual 2.0M (2021-11-15); 50.5x the same period a year earlier
Insider net buying (open market)
Month from 1 Apr 2022: $102K published
Month from 1 Jan 2023: $156K published
Month from 1 Oct 2023: $90K published
Month from 1 Aug 2025: $206K published
Month from 1 Nov 2025: -$314 published
Month from 1 Dec 2025: $101K published
Revenue per quarter
Quarter ended 31 Dec 2021: $8.5M, -56% on a year earlier; public on 1 Apr 2022
Quarter ended 31 Mar 2022: $16.1M, +42% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $8.8M, +36% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $14.2M, +18% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $8.6M, +0.8% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $9.6M, -40% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $35.1M, +301% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $10.3M, -27% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $10.5M, +22% on a year earlier; public on 15 Mar 2024
Quarter ended 31 Mar 2024: $3.7M, -61% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $13.5M, -62% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $18.0M, +74% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $18.2M, +74% on a year earlier; public on 18 Mar 2025
Quarter ended 31 Mar 2025: $10.1M, +170% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $15.7M, +16% on a year earlier; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $17.9M, -0.6% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $9.1M, -50% on a year earlier; public on 19 Mar 2026
Quarter ended 31 Mar 2026: $33.8M, +234% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $19.9M, +27% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $21.9M, +23% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $448K, +63% on a year earlier; public on 1 Apr 2022
Quarter ended 31 Mar 2022: $229K, -41% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $128K, -54% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $58K, -83% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $213K, -52% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $248K, +8.3% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $204K, +59% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $447K, +671% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $250K, +17% on a year earlier; public on 15 Mar 2024
Quarter ended 31 Mar 2024: $598K, +141% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $172K, -16% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $87K, -81% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $425K, +70% on a year earlier; public on 18 Mar 2025
Quarter ended 31 Mar 2025: $306K, -49% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $431K, +151% on a year earlier; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $498K, +472% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $403K, -5.2% on a year earlier; public on 19 Mar 2026
Quarter ended 31 Mar 2026: $761K, +149% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $593K, +38% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $737K, +48% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 25; public on 14 Feb 2022
31 Mar 2022 report: 27; public on 16 May 2022
30 Jun 2022 report: 25; public on 15 Aug 2022
30 Sep 2022 report: 22; public on 14 Nov 2022
31 Dec 2022 report: 21; public on 14 Feb 2023
31 Mar 2023 report: 29; public on 15 May 2023
30 Jun 2023 report: 58; public on 14 Aug 2023
30 Sep 2023 report: 57; public on 14 Nov 2023
31 Dec 2023 report: 60; public on 14 Feb 2024
31 Mar 2024 report: 58; public on 15 May 2024
30 Jun 2024 report: 60; public on 14 Aug 2024
30 Sep 2024 report: 40; public on 14 Nov 2024
31 Dec 2024 report: 45; public on 14 Feb 2025
31 Mar 2025 report: 62; public on 15 May 2025
30 Jun 2025 report: 60; public on 14 Aug 2025
30 Sep 2025 report: 76; public on 14 Nov 2025
31 Dec 2025 report: 82; public on 17 Feb 2026
31 Mar 2026 report: 95; public on 15 May 2026
30 Jun 2026 report: 101; public on 14 Aug 2026
30 Sep 2026 report: 106; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 106 (30 Sep 2026), 1.8× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $101K in the last 12 months (the 12 months before: $206K).
  • Revenue per quarter: Revenue $21.9M in the latest quarter, +23% on a year earlier.
  • Capital spending per quarter: Capital spending $737K in the latest quarter, +48% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 10 insider trades

No trades in the last 90 days; the latest was filed 23 Dec 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
23 Dec 2025Dror BashanPRESIDENT AND CEOBuy56,000$1.81$101KForm 4
19 Nov 2025Amos Bar-ShalevDirectorSell168$1.87$314Form 4
12 Aug 2025Aharon SchwartzDirectorBuy129,000$1.60$206KForm 4
20 Oct 2023Dror BashanPRESIDENT AND CEOBuy64,516$1.40$90KForm 4
5 Jan 2023Aharon SchwartzDirectorBuy110,000$1.42$156KForm 4
13 Apr 2022Dror BashanPresident and CEOBuy68,000$1.50$102KForm 4
3 Jun 2021Dan Oren and 1 other10% ownerSell918,717$2.27$2.1MForm 4
13 Apr 2020Aharon SchwartzDirectorBuy64,000$2.43$156KForm 4

106 institutions reported shares at the end of Q3 2026, 19% of the shares outstanding; 15 opened a position, 14 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.4.2M4.98%$11.6M+154K+3.8%
State Street Corp1.2M1.37%$3.2M+174K+18%
Geode Capital Management, LLC997K1.18%$2.8M+17K+1.7%
Renaissance Technologies LLC988K1.17%$2.7M-108K-9.8%
Goldman Sachs Group Inc889K1.05%$2.5M+413K+87%
Northern Trust Corp832K0.99%$2.3M-91K-9.8%
Dimensional Fund Advisors LP717K0.85%$2.0M+224K+45%
Vanguard Portfolio Management LLC557K0.66%$1.5M+47K+9.1%
Stratos Wealth Partners, LTD.400K0.47%$1.1M-100K-20%
Creative Planning375K0.45%$1.0MNew+375K

Company events

All 36 company events

Nothing in 12 months; the latest was filed 22 Aug 2025. Results releases and routine reports are left out.

FiledWhat happenedSource
22 Aug 2025Signed a major agreement8-K
21 Jul 2025Director or officer change; Signed a major agreement8-K
23 Apr 2025Director or officer change8-K
17 Mar 2025Signed a major agreement8-K
12 Sep 2023Director or officer change8-K
27 Feb 2023Signed a major agreement8-K
1 Sep 2022Signed a major agreement8-K
30 Jun 2022Director or officer changeSame filing: shareholder vote results8-K
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

8 Aug 2023confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

Protalix BioTherapeutics (PLX): had 7.3M shares sold short in the 30 Jun 2023 report, 3.1× the same report last year; it also reported revenue of $35.1M for the quarter ended 30 Jun 2023, 4.0× the same quarter last year; and it saw 33 13F filers open a new position in the quarter ended 30 Jun 2023, 8.2× the same quarter last year. Three unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 13 Jul 2023
  • Short interest and volume: Short interest spike, became public on 26 Jul 2023
  • Financials: Quarterly revenue change, became public on 8 Aug 2023
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2023
2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M2023-06-15: 7.0M2023-06-30: 7.3M
The 30 Jun 2023 report against the 24 reports before it. this reportearliernormal: 2.1M
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 13 Jul 2023

Protalix BioTherapeutics had 7.3M shares sold short in the 30 Jun 2023 report, 3.1× the same report last year.

This period
7.3M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
589K
How far from its usual level
+5.9
Same report last year
2.4M
History used
2,009 days
2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M2023-06-15: 7.0M2023-06-30: 7.3M
the 30 Jun 2023 report24 earlier reportsnormal: 2.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jul 2023

Protalix BioTherapeutics had 6.3M shares sold short in the 14 Jul 2023 report, 2.9× the same report last year.

This period
6.3M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
608K
How far from its usual level
+4.6
Same report last year
2.2M
History used
2,023 days
2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M2023-06-15: 7.0M2023-06-30: 7.3M2023-07-14: 6.3M
the 14 Jul 2023 report24 earlier reportsnormal: 2.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 8 Aug 2023

Protalix BioTherapeutics reported revenue of $35.1M for the quarter ended 30 Jun 2023, 4.0× the same quarter last year.

This period
$35.1M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$9.2M
Typical spread (median absolute deviation)
$1.7M
How far from its usual level
+10.4
Same quarter last year
$8.8M
History used
4,748 days
2021-06-30: $6.4M2021-09-30: $12.1M2021-12-31: $8.5M2022-03-31: $16.1M2022-06-30: $8.8M2022-09-30: $14.2M2022-12-31: $8.6M2023-03-31: $9.6M2023-06-30: $35.1M
the quarter ended 30 Jun 20238 earlier quartersnormal: $9.2M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

Protalix BioTherapeutics saw 33 13F filers open a new position in the quarter ended 30 Jun 2023, 8.2× the same quarter last year.

This period
33 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
4.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+7.7
Same quarter last year
4
History used
3,560 days
2021-06-30: 112021-09-30: 52021-12-31: 22022-03-31: 82022-06-30: 42022-09-30: 22022-12-31: 32023-03-31: 102023-06-30: 33
the quarter ended 30 Jun 20238 earlier quartersnormal: 4.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

17 Aug 2021confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Protalix BioTherapeutics (PLX): had 2.5M shares sold short in the 15 Jul 2021 report, 6.9× the same report last year, while it reported revenue of $6.4M for the quarter ended 30 Jun 2021, 41% below the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Short interest and volume: Short interest spike, became public on 27 Jul 2021
  • Financials: Quarterly revenue change, became public on 17 Aug 2021
  • Short interest and volume: Short interest spike, became public on 11 Aug 2021
2020-07-15: 355K2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M
The 15 Jul 2021 report against the 24 reports before it. this reportearliernormal: 498K
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 27 Jul 2021

Protalix BioTherapeutics had 2.5M shares sold short in the 15 Jul 2021 report, 6.9× the same report last year.

This period
2.5M (the 15 Jul 2021 report)
Normal report (median of 24 earlier)
498K
Typical spread (median absolute deviation)
353K
How far from its usual level
+3.8
Same report last year
355K
History used
1,294 days
2020-07-15: 355K2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M
the 15 Jul 2021 report24 earlier reportsnormal: 498K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 17 Aug 2021

Protalix BioTherapeutics reported revenue of $6.4M for the quarter ended 30 Jun 2021, 41% below the same quarter last year.

This period
$6.4M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$11.8M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
-3.1
Same quarter last year
$11.0M
History used
4,018 days
2019-03-31: $10.4M2019-06-30: $12.2M2019-09-30: $14.2M2020-03-31: $21.6M2020-06-30: $11.0M2020-09-30: $10.8M2020-12-31: $19.5M2021-03-31: $11.3M2021-06-30: $6.4M
the quarter ended 30 Jun 20218 earlier quartersnormal: $11.8M

Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 11 Aug 2021

Protalix BioTherapeutics had 2.5M shares sold short in the 30 Jul 2021 report, 7.2× the same report last year.

This period
2.5M (the 30 Jul 2021 report)
Normal report (median of 24 earlier)
505K
Typical spread (median absolute deviation)
373K
How far from its usual level
+3.7
Same report last year
350K
History used
1,309 days
2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M2021-07-30: 2.5M
the 30 Jul 2021 report24 earlier reportsnormal: 505K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 14 May 2026Financials change

    reported revenue of $33.8M for the quarter ended 31 Mar 2026, 3.3× the same quarter last year.

    Same quarter last year: $10.1M; its normal quarter is $14.6M.

    See the evidence
    This period
    $33.8M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $14.6M
    Typical spread (median absolute deviation)
    $3.5M
    How far from its usual level
    +3.7
    Same quarter last year
    $10.1M
    History used
    3,652 days
    2024-03-31: $3.7M2024-06-30: $13.5M2024-09-30: $18.0M2024-12-31: $18.2M2025-03-31: $10.1M2025-06-30: $15.7M2025-09-30: $17.9M2025-12-31: $9.1M2026-03-31: $33.8M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $14.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 24 Dec 2025Insiders record

    Bashan Dror (PRESIDENT AND CEO) bought 56,000 shares of PLX ($101,360) (dated 23 Dec 2025)

  3. 14 Aug 2025Institutional holdings change

    saw 27 13F filers open a new position in the quarter ended 30 Jun 2025, 1.1× the same quarter last year.

    Same quarter last year: 25; its normal quarter is 8.5.

    See the evidence
    This period
    27 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    8.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +4.2
    Same quarter last year
    25
    History used
    4,291 days
    2023-06-30: 332023-09-30: 82023-12-31: 92024-03-31: 72024-06-30: 252024-09-30: 42024-12-31: 72025-03-31: 212025-06-30: 27
    the quarter ended 30 Jun 20258 earlier quartersnormal: 8.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  4. 13 Aug 2025Insiders record

    Schwartz Aharon (director) bought 129,000 shares of PLX ($206,400) (dated 12 Aug 2025)

  5. 21 Jul 2025Filings record

    Director or officer change

  6. 15 May 2025Institutional holdings change

    saw 21 13F filers open a new position in the quarter ended 31 Mar 2025, 3.0× the same quarter last year.

    Same quarter last year: 7; its normal quarter is 8.5.

    See the evidence
    This period
    21 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    8.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +4.2
    Same quarter last year
    7
    History used
    4,200 days
    2023-03-31: 102023-06-30: 332023-09-30: 82023-12-31: 92024-03-31: 72024-06-30: 252024-09-30: 42024-12-31: 72025-03-31: 21
    the quarter ended 31 Mar 20258 earlier quartersnormal: 8.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  7. 23 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 23 Apr 2025Filings record

    Director or officer change

  9. 14 Aug 2024Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 30 Jun 2024, 24% below the same quarter last year.

    Same quarter last year: 33; its normal quarter is 7.5.

    See the evidence
    This period
    25 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +3.9
    Same quarter last year
    33
    History used
    3,926 days
    2022-06-30: 42022-09-30: 22022-12-31: 32023-03-31: 102023-06-30: 332023-09-30: 82023-12-31: 92024-03-31: 72024-06-30: 25
    the quarter ended 30 Jun 20248 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  10. 21 Oct 2023Insiders record

    Bashan Dror (PRESIDENT AND CEO) bought 64,516 shares of PLX ($90,484) (dated 20 Oct 2023)

  11. 12 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 12 Sep 2023Filings record

    Director or officer change

  13. 14 Aug 2023Institutional holdings change

    saw 33 13F filers open a new position in the quarter ended 30 Jun 2023, 8.2× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 4.5.

    See the evidence
    This period
    33 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    4.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +7.7
    Same quarter last year
    4
    History used
    3,560 days
    2021-06-30: 112021-09-30: 52021-12-31: 22022-03-31: 82022-06-30: 42022-09-30: 22022-12-31: 32023-03-31: 102023-06-30: 33
    the quarter ended 30 Jun 20238 earlier quartersnormal: 4.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  14. 8 Aug 2023several at once

    had 7.3M shares sold short in the 30 Jun 2023 report, 3.1× the same report last year; it also reported revenue of $35.1M for the quarter ended 30 Jun 2023, 4.0× the same quarter last year; and it saw 33 13F filers open a new position in the quarter ended 30 Jun 2023, 8.2× the same quarter last year. Three unrelated kinds of activity within 28 days.

    See the evidence (4 changes)

    Short interest and volume: Short interest spike became public on 13 Jul 2023

    Protalix BioTherapeutics had 7.3M shares sold short in the 30 Jun 2023 report, 3.1× the same report last year.

    This period
    7.3M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    589K
    How far from its usual level
    +5.9
    Same report last year
    2.4M
    History used
    2,009 days
    2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M2023-06-15: 7.0M2023-06-30: 7.3M
    the 30 Jun 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jul 2023

    Protalix BioTherapeutics had 6.3M shares sold short in the 14 Jul 2023 report, 2.9× the same report last year.

    This period
    6.3M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    608K
    How far from its usual level
    +4.6
    Same report last year
    2.2M
    History used
    2,023 days
    2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M2023-06-15: 7.0M2023-06-30: 7.3M2023-07-14: 6.3M
    the 14 Jul 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 8 Aug 2023

    Protalix BioTherapeutics reported revenue of $35.1M for the quarter ended 30 Jun 2023, 4.0× the same quarter last year.

    This period
    $35.1M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $9.2M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    +10.4
    Same quarter last year
    $8.8M
    History used
    4,748 days
    2021-06-30: $6.4M2021-09-30: $12.1M2021-12-31: $8.5M2022-03-31: $16.1M2022-06-30: $8.8M2022-09-30: $14.2M2022-12-31: $8.6M2023-03-31: $9.6M2023-06-30: $35.1M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $9.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

    Protalix BioTherapeutics saw 33 13F filers open a new position in the quarter ended 30 Jun 2023, 8.2× the same quarter last year.

    This period
    33 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    4.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +7.7
    Same quarter last year
    4
    History used
    3,560 days
    2021-06-30: 112021-09-30: 52021-12-31: 22022-03-31: 82022-06-30: 42022-09-30: 22022-12-31: 32023-03-31: 102023-06-30: 33
    the quarter ended 30 Jun 20238 earlier quartersnormal: 4.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 8 Aug 2023Financials change

    reported revenue of $35.1M for the quarter ended 30 Jun 2023, 4.0× the same quarter last year.

    Same quarter last year: $8.8M; its normal quarter is $9.2M.

    See the evidence
    This period
    $35.1M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $9.2M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    +10.4
    Same quarter last year
    $8.8M
    History used
    4,748 days
    2021-06-30: $6.4M2021-09-30: $12.1M2021-12-31: $8.5M2022-03-31: $16.1M2022-06-30: $8.8M2022-09-30: $14.2M2022-12-31: $8.6M2023-03-31: $9.6M2023-06-30: $35.1M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $9.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  16. 26 Jul 2023Short interest and volume change

    had 6.3M shares sold short in the 14 Jul 2023 report, 2.9× the same report last year.

    Same report last year: 2.2M; its normal report is 2.1M.

    See the evidence
    This period
    6.3M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    608K
    How far from its usual level
    +4.6
    Same report last year
    2.2M
    History used
    2,023 days
    2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M2023-06-15: 7.0M2023-06-30: 7.3M2023-07-14: 6.3M
    the 14 Jul 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 13 Jul 2023Short interest and volume change

    had 7.3M shares sold short in the 30 Jun 2023 report, 3.1× the same report last year.

    Same report last year: 2.4M; its normal report is 2.1M.

    See the evidence
    This period
    7.3M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    589K
    How far from its usual level
    +5.9
    Same report last year
    2.4M
    History used
    2,009 days
    2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M2023-06-15: 7.0M2023-06-30: 7.3M
    the 30 Jun 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 28 Jun 2023Short interest and volume change

    had 7.0M shares sold short in the 15 Jun 2023 report, 2.7× the same report last year.

    Same report last year: 2.6M; its normal report is 2.1M.

    See the evidence
    This period
    7.0M (the 15 Jun 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    587K
    How far from its usual level
    +5.6
    Same report last year
    2.6M
    History used
    1,994 days
    2022-06-15: 2.6M2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M2023-06-15: 7.0M
    the 15 Jun 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 10 Jun 2023Short interest and volume change

    had 7.3M shares sold short in the 31 May 2023 report, 2.7× the same report last year.

    Same report last year: 2.7M; its normal report is 2.1M.

    See the evidence
    This period
    7.3M (the 31 May 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    587K
    How far from its usual level
    +5.9
    Same report last year
    2.7M
    History used
    1,979 days
    2022-05-31: 2.7M2022-06-15: 2.6M2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M2023-05-31: 7.3M
    the 31 May 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 25 May 2023Short interest and volume change

    had 8.1M shares sold short in the 15 May 2023 report, 2.1× the same report last year.

    Same report last year: 3.8M; its normal report is 2.1M.

    See the evidence
    This period
    8.1M (the 15 May 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    587K
    How far from its usual level
    +6.9
    Same report last year
    3.8M
    History used
    1,963 days
    2022-05-13: 3.8M2022-05-31: 2.7M2022-06-15: 2.6M2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M2023-05-15: 8.1M
    the 15 May 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 10 May 2023Short interest and volume change

    had 7.4M shares sold short in the 28 Apr 2023 report, 1.6× the same report last year.

    Same report last year: 4.5M; its normal report is 2.1M.

    See the evidence
    This period
    7.4M (the 28 Apr 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    587K
    How far from its usual level
    +6.1
    Same report last year
    4.5M
    History used
    1,946 days
    2022-04-29: 4.5M2022-05-13: 3.8M2022-05-31: 2.7M2022-06-15: 2.6M2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M2023-04-28: 7.4M
    the 28 Apr 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 26 Apr 2023Short interest and volume change

    had 6.4M shares sold short in the 14 Apr 2023 report, 1.1× the same report last year.

    Same report last year: 5.6M; its normal report is 2.1M.

    See the evidence
    This period
    6.4M (the 14 Apr 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    587K
    How far from its usual level
    +5.0
    Same report last year
    5.6M
    History used
    1,932 days
    2022-04-14: 5.6M2022-04-29: 4.5M2022-05-13: 3.8M2022-05-31: 2.7M2022-06-15: 2.6M2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M2023-04-14: 6.4M
    the 14 Apr 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 13 Apr 2023Short interest and volume change

    had 5.4M shares sold short in the 31 Mar 2023 report, 1.3× the same report last year.

    Same report last year: 4.1M; its normal report is 2.1M.

    See the evidence
    This period
    5.4M (the 31 Mar 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    587K
    How far from its usual level
    +3.8
    Same report last year
    4.1M
    History used
    1,918 days
    2022-03-31: 4.1M2022-04-14: 5.6M2022-04-29: 4.5M2022-05-13: 3.8M2022-05-31: 2.7M2022-06-15: 2.6M2022-06-30: 2.4M2022-07-15: 2.2M2022-07-29: 2.1M2022-08-15: 1.6M2022-08-31: 1.5M2022-09-15: 1.5M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.7M2022-11-15: 1.7M2022-11-30: 1.7M2022-12-15: 1.7M2022-12-30: 1.8M2023-01-13: 2.1M2023-01-31: 3.3M2023-02-15: 3.3M2023-02-28: 4.8M2023-03-15: 5.1M2023-03-31: 5.4M
    the 31 Mar 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 6 Jan 2023Insiders record

    Schwartz Aharon (director) bought 110,000 shares of PLX ($156,200) (dated 5 Jan 2023)

  25. 30 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 30 Jun 2022Filings record

    Director or officer change

  27. 14 Apr 2022Insiders record

    Bashan Dror (President and CEO) bought 68,000 shares of PLX ($102,000) (dated 13 Apr 2022)

  28. 25 Nov 2021Short interest and volume change

    had 6.6M shares sold short in the 15 Nov 2021 report, 50× the same report last year.

    Same report last year: 131K; its normal report is 2.0M.

    See the evidence
    This period
    6.6M (the 15 Nov 2021 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    627K
    How far from its usual level
    +5.0
    Same report last year
    131K
    History used
    1,417 days
    2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M2021-07-30: 2.5M2021-08-13: 2.4M2021-08-31: 4.9M2021-09-15: 6.9M2021-09-30: 7.3M2021-10-15: 7.6M2021-10-29: 6.8M2021-11-15: 6.6M
    the 15 Nov 2021 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 10 Nov 2021Short interest and volume change

    had 6.8M shares sold short in the 29 Oct 2021 report, 51× the same report last year.

    Same report last year: 135K; its normal report is 1.9M.

    See the evidence
    This period
    6.8M (the 29 Oct 2021 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    672K
    How far from its usual level
    +4.9
    Same report last year
    135K
    History used
    1,400 days
    2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M2021-07-30: 2.5M2021-08-13: 2.4M2021-08-31: 4.9M2021-09-15: 6.9M2021-09-30: 7.3M2021-10-15: 7.6M2021-10-29: 6.8M
    the 29 Oct 2021 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 27 Oct 2021Short interest and volume change

    had 7.6M shares sold short in the 15 Oct 2021 report, 45× the same report last year.

    Same report last year: 167K; its normal report is 1.7M.

    See the evidence
    This period
    7.6M (the 15 Oct 2021 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    831K
    How far from its usual level
    +4.7
    Same report last year
    167K
    History used
    1,386 days
    2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M2021-07-30: 2.5M2021-08-13: 2.4M2021-08-31: 4.9M2021-09-15: 6.9M2021-09-30: 7.3M2021-10-15: 7.6M
    the 15 Oct 2021 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 13 Oct 2021Short interest and volume change

    had 7.3M shares sold short in the 30 Sep 2021 report, 46× the same report last year.

    Same report last year: 157K; its normal report is 1.6M.

    See the evidence
    This period
    7.3M (the 30 Sep 2021 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +3.8
    Same report last year
    157K
    History used
    1,371 days
    2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M2021-07-30: 2.5M2021-08-13: 2.4M2021-08-31: 4.9M2021-09-15: 6.9M2021-09-30: 7.3M
    the 30 Sep 2021 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 25 Sep 2021Short interest and volume change

    had 6.9M shares sold short in the 15 Sep 2021 report, 14× the same report last year.

    Same report last year: 505K; its normal report is 1.5M.

    See the evidence
    This period
    6.9M (the 15 Sep 2021 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +3.6
    Same report last year
    505K
    History used
    1,356 days
    2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M2021-07-30: 2.5M2021-08-13: 2.4M2021-08-31: 4.9M2021-09-15: 6.9M
    the 15 Sep 2021 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 17 Aug 2021several at once

    had 2.5M shares sold short in the 15 Jul 2021 report, 6.9× the same report last year, while it reported revenue of $6.4M for the quarter ended 30 Jun 2021, 41% below the same quarter last year. Two unrelated kinds of activity within 21 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 27 Jul 2021

    Protalix BioTherapeutics had 2.5M shares sold short in the 15 Jul 2021 report, 6.9× the same report last year.

    This period
    2.5M (the 15 Jul 2021 report)
    Normal report (median of 24 earlier)
    498K
    Typical spread (median absolute deviation)
    353K
    How far from its usual level
    +3.8
    Same report last year
    355K
    History used
    1,294 days
    2020-07-15: 355K2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M
    the 15 Jul 2021 report24 earlier reportsnormal: 498K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 17 Aug 2021

    Protalix BioTherapeutics reported revenue of $6.4M for the quarter ended 30 Jun 2021, 41% below the same quarter last year.

    This period
    $6.4M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $11.8M
    Typical spread (median absolute deviation)
    $1.2M
    How far from its usual level
    -3.1
    Same quarter last year
    $11.0M
    History used
    4,018 days
    2019-03-31: $10.4M2019-06-30: $12.2M2019-09-30: $14.2M2020-03-31: $21.6M2020-06-30: $11.0M2020-09-30: $10.8M2020-12-31: $19.5M2021-03-31: $11.3M2021-06-30: $6.4M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $11.8M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 11 Aug 2021

    Protalix BioTherapeutics had 2.5M shares sold short in the 30 Jul 2021 report, 7.2× the same report last year.

    This period
    2.5M (the 30 Jul 2021 report)
    Normal report (median of 24 earlier)
    505K
    Typical spread (median absolute deviation)
    373K
    How far from its usual level
    +3.7
    Same report last year
    350K
    History used
    1,309 days
    2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M2021-07-30: 2.5M
    the 30 Jul 2021 report24 earlier reportsnormal: 505K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  34. 17 Aug 2021Financials change

    reported revenue of $6.4M for the quarter ended 30 Jun 2021, 41% below the same quarter last year.

    Same quarter last year: $11.0M; its normal quarter is $11.8M.

    See the evidence
    This period
    $6.4M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $11.8M
    Typical spread (median absolute deviation)
    $1.2M
    How far from its usual level
    -3.1
    Same quarter last year
    $11.0M
    History used
    4,018 days
    2019-03-31: $10.4M2019-06-30: $12.2M2019-09-30: $14.2M2020-03-31: $21.6M2020-06-30: $11.0M2020-09-30: $10.8M2020-12-31: $19.5M2021-03-31: $11.3M2021-06-30: $6.4M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $11.8M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 11 Aug 2021Short interest and volume change

    had 2.5M shares sold short in the 30 Jul 2021 report, 7.2× the same report last year.

    Same report last year: 350K; its normal report is 505K.

    See the evidence
    This period
    2.5M (the 30 Jul 2021 report)
    Normal report (median of 24 earlier)
    505K
    Typical spread (median absolute deviation)
    373K
    How far from its usual level
    +3.7
    Same report last year
    350K
    History used
    1,309 days
    2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M2021-07-30: 2.5M
    the 30 Jul 2021 report24 earlier reportsnormal: 505K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 27 Jul 2021Short interest and volume change

    had 2.5M shares sold short in the 15 Jul 2021 report, 6.9× the same report last year.

    Same report last year: 355K; its normal report is 498K.

    See the evidence
    This period
    2.5M (the 15 Jul 2021 report)
    Normal report (median of 24 earlier)
    498K
    Typical spread (median absolute deviation)
    353K
    How far from its usual level
    +3.8
    Same report last year
    355K
    History used
    1,294 days
    2020-07-15: 355K2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M2021-06-30: 2.1M2021-07-15: 2.5M
    the 15 Jul 2021 report24 earlier reportsnormal: 498K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 2 Jul 2021Filings record

    A major agreement ended

  38. 26 Jun 2021Short interest and volume change

    had 1.9M shares sold short in the 15 Jun 2021 report, 4.2× the same report last year.

    Same report last year: 453K; its normal report is 471K.

    See the evidence
    This period
    1.9M (the 15 Jun 2021 report)
    Normal report (median of 24 earlier)
    471K
    Typical spread (median absolute deviation)
    247K
    How far from its usual level
    +3.9
    Same report last year
    453K
    History used
    1,264 days
    2020-06-15: 453K2020-06-30: 459K2020-07-15: 355K2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M2021-06-15: 1.9M
    the 15 Jun 2021 report24 earlier reportsnormal: 471K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 10 Jun 2021Short interest and volume change

    had 2.4M shares sold short in the 28 May 2021 report, 9.6× the same report last year.

    Same report last year: 255K; its normal report is 456K.

    See the evidence
    This period
    2.4M (the 28 May 2021 report)
    Normal report (median of 24 earlier)
    456K
    Typical spread (median absolute deviation)
    188K
    How far from its usual level
    +7.1
    Same report last year
    255K
    History used
    1,246 days
    2020-05-29: 255K2020-06-15: 453K2020-06-30: 459K2020-07-15: 355K2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M2021-05-28: 2.4M
    the 28 May 2021 report24 earlier reportsnormal: 456K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 26 May 2021Short interest and volume change

    had 2.6M shares sold short in the 14 May 2021 report, 13× the same report last year.

    Same report last year: 196K; its normal report is 404K.

    See the evidence
    This period
    2.6M (the 14 May 2021 report)
    Normal report (median of 24 earlier)
    404K
    Typical spread (median absolute deviation)
    136K
    How far from its usual level
    +11.0
    Same report last year
    196K
    History used
    1,232 days
    2020-05-15: 196K2020-05-29: 255K2020-06-15: 453K2020-06-30: 459K2020-07-15: 355K2020-07-31: 350K2020-08-14: 483K2020-08-31: 491K2020-09-15: 505K2020-09-30: 157K2020-10-15: 167K2020-10-30: 135K2020-11-13: 131K2020-11-30: 294K2020-12-15: 283K2020-12-31: 291K2021-01-15: 282K2021-01-29: 506K2021-02-12: 1.4M2021-02-26: 1.5M2021-03-15: 1.6M2021-03-31: 1.6M2021-04-15: 1.9M2021-04-30: 2.5M2021-05-14: 2.6M
    the 14 May 2021 report24 earlier reportsnormal: 404K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 63 entries; narrow the window or the kind of data to see older ones.

Not listed: 181 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001006281
Ticker
PLX
Domain
protalix.com
Hq location
NJ|HACKENSACK|07601 (1 unverified)
Name
EMBASSY ACQUISITION CORP, ORTHODONTIX INC, Protalix BioTherapeutics, Inc.
Wikidata
Q7251166
Wikipedia
Protalix BioTherapeutics
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)194 records3 Mar 2016 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1176 data points31 Dec 2008 to 1 Nov 2026
  • SEC Form 4 insider transactions10 records, 40 data points6 Dec 2016 to 23 Dec 2025
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026